PIK3CA and Hyperglycemia: A 63-year-old Pacific Islander female, with no personal or family history of diabetes mellitus or recent glucocorticoid usage, was referred to the Diabetes Center for management of new-onset hyperglycemia of 439.2 mg/dL (24.4 mmol/L) following 2 weeks of treatment with inavolisib, a trial drug inhibiting the PIK3CA pathway, and fulvestrant.